 Cue Biopharma, Inc. CUE, a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it has entered into a research collaboration agreement with Dr. Michael Dustin and the University of Oxford to determine the molecular mechanisms underlying the activity of its IL-2 based CUE-100 series Immuno-STATTM Selective Targeting and Alteration of T cells Biologics. Cue Biopharma is pleased to enter into this strategic collaboration with Dr. Dustin and the University of Oxford, said Saso Cemerski, senior director of immuno-oncology discovery and translational immunology at Cue Biopharma. 